- Home
- Publications
- Publication Search
- Publication Details
Title
Making HPV vaccination available to girls everywhere
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2018-08-24
DOI
10.1002/ijgo.12656
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Progress in HPV vaccination in low- and lower-middle-income countries
- (2017) D. Scott LaMontagne et al. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS
- Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial
- (2017) Mahboobeh Safaeian et al. JNCI-Journal of the National Cancer Institute
- Final efficacy, immunogenicity, and safety analyses of a nine-valent human papillomavirus vaccine in women aged 16–26 years: a randomised, double-blind trial
- (2017) Warner K Huh et al. LANCET
- Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point—registry-based follow-up of three cohorts from randomized trials
- (2017) Matti Lehtinen et al. BMJ Open
- Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial
- (2017) Mahboobeh Safaeian et al. JNCI-Journal of the National Cancer Institute
- Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects
- (2017) Siobhan Botwright et al. PLoS One
- Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014
- (2016) Joël Ladner et al. BMC HEALTH SERVICES RESEARCH
- Argentina’s Successful Implementation Of A National Human Papillomavirus Vaccination Program
- (2016) Hannah Patel et al. HEALTH AFFAIRS
- Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
- (2016) Cosette M Wheeler et al. LANCET INFECTIOUS DISEASES
- Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study
- (2016) Rengaswamy Sankaranarayanan et al. LANCET ONCOLOGY
- Manufacturing costs of HPV vaccines for developing countries
- (2016) Chaevia Clendinen et al. VACCINE
- Global estimates of human papillomavirus vaccination coverage by region and income level: a pooled analysis
- (2016) Laia Bruni et al. Lancet Global Health
- National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2015
- (2016) Sarah Reagan-Steiner et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions
- (2015) Beatriz Serrano et al. EUROPEAN JOURNAL OF CANCER
- Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis
- (2015) Mélanie Drolet et al. LANCET INFECTIOUS DISEASES
- Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials
- (2015) Aimée R Kreimer et al. LANCET ONCOLOGY
- HPV-FASTER: broadening the scope for prevention of HPV-related cancer
- (2015) F. Xavier Bosch et al. Nature Reviews Clinical Oncology
- A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women
- (2015) Elmar A. Joura et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cervical cancer screening and HPV vaccine acceptability among rural and urban women in Kilimanjaro Region, Tanzania
- (2015) M. S. Cunningham et al. BMJ Open
- Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model
- (2015) M. Jit et al. BMJ-British Medical Journal
- Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model
- (2015) M. Jit et al. BMJ-British Medical Journal
- Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries
- (2015) D Scott LaMontagne et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Systematic review of human papillomavirus vaccine coadministration
- (2014) Alinea S. Noronha et al. VACCINE
- Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine
- (2014) Paulo S Naud et al. Human Vaccines & Immunotherapeutics
- Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study
- (2014) Mark Jit et al. Lancet Global Health
- Model-Based Impact and Cost-Effectiveness of Cervical Cancer Prevention in Sub-Saharan Africa
- (2013) Jane J. Kim et al. VACCINE
- Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths
- (2013) Georges Van Kriekinge et al. VACCINE
- Achieving high coverage in Rwanda’s national human papillomavirus vaccination programme
- (2012) Agnes Binagwaho et al. BULLETIN OF THE WORLD HEALTH ORGANIZATION
- Population-Level Impact of the Bivalent, Quadrivalent, and Nonavalent Human Papillomavirus Vaccines: A Model–Based Analysis
- (2012) Nicolas Van de Velde et al. JNCI-Journal of the National Cancer Institute
- End-of-study safety, immunogenicity and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age
- (2011) X Castellsagué et al. BRITISH JOURNAL OF CANCER
- Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial
- (2011) Matti Lehtinen et al. LANCET ONCOLOGY
- Safety and Immunogenicity of a Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Vaccine in HIV-Infected Children 7 to 12 Years Old
- (2010) Myron J Levin et al. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
- Intellectual property, technology transfer and manufacture of low-cost HPV vaccines in India
- (2010) Swathi Padmanabhan et al. NATURE BIOTECHNOLOGY
- Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines
- (2010) A. Arguedas et al. VACCINE
- Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries
- (2008) Sue J. Goldie et al. VACCINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started